Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

NCT03759379 is registered in ClinicalTrials.gov with Alnylam Pharmaceuticals as lead sponsor.

NCT NCT03759379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03759379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
Lead sponsor
Alnylam Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
February 14, 2019
Completion date
November 5, 2025
Enrollment
164 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

amyloidosis, hereditary, transthyretin amyloidosis